William Blair Upgrades Pyxis Oncology to Outperform on Strong Phase 1 Data for MICVO in Head and Neck Cancer
Blair raised its rating on PYXS following updated Phase 1 results for MICVO, citing 39% response rate, 9.2-month durability, and Phase 3 plans.